{"name":"Transposon Therapeutics, Inc.","slug":"transposon-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRHJtakxvdkRYZ3J2azgyVWJiMVJpdDNZSFBQbEFfakVCcjZ0dUsydlVOMTlxa2pFdUdVengtendsdmJ2UG9nYzB5aVBJc1pYMmJwbnVkeTdlZ0xEMDRVVVBrYnFrN1lsNmo4VGlKdkdCSnV0c3VkdzlmRFluXzgtbmVNQURBNFpKa00tZDlWeXBod3hLR3ExTmpLbUxRTGFkMThDV0FmMk54VHJpeEhWbzRoSEhXVUlsYi1Ca2QyV3dPbWxvV0ZqMGFqbnN4Rk5Wd3N6ZUZ0dVR1MGpMdzF6eFhLN1l2a1MxbnFock1VU0ZMY0RHRTBHUmVB?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight - Barchart.com","headline":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNenJOQkY3Mk5hWVVnRFVKTVZ6T2tqWDJtOHhfbThzRlEweHlyOUFQX2hwVjlOcjVtUjNKeDhBV0pvMk5nSUtoWDk1dTZxZkV4dmZNaVVsZUg2ZmViZXI2QTdxYkdtSmlaRDNvblNvRlZaRnF6SzZPU0ZXazR2d3BWT3JseDdjS1Z1YmE1ZXhCWXN5U2cw?oc=5","date":"2025-12-09","type":"pipeline","source":"Yahoo Finance","summary":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance","headline":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQQzZONnNQY1N0YlhhTjlPVmNOS044ZzJZaDJhNXU1elZkTzh4ZXpKS09aN1hyOUxvei16Y2ZyTWNhTFRkQ0ZzVDBRTVhXSnNVcFllOXA5czhXdE0xZ0lYckYzRDZJczBod2JVM3FwRXlhREVseXN1d2NCOTZ0UmlCVGJCYjByV3RPLVBvdzVxU3p5WlZqVHIwODhTaHZuU1kwOENBX0NVbExvNWI3WF9WTGdBMlluQ21rdXRLZ2FWYTZrQU1TdExPRUh6a09TaUEyeDNIenRpOG41d2lUODBjdGNFMWpEN2JYWkh3NkZMT3M?oc=5","date":"2025-08-07","type":"pipeline","source":"The AI Journal","summary":"Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The AI Journal","headline":"Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunoth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdzFzVmY2Ml84RXJWRGRXRlNYR0NlYnN1QjRhVjc4SnN2b1F1RWFfSlBDeFlzdXVIVjRUaUhJLXEtVl96WDZNRm5tWHZjcUhzUGhNVWNMV3NWb2ZVSVRtYUNxamVKb1RJZDZVNjR2MlpqbTROVGxISHlxNi1PNFMzV2FhejhKYTRiS3VkM01NM0VldmFEcWt6c1dwc3ZfZXFHLTVtNzlfc3hvY0dVRUw1Zi1ZTHh5Y2dVTzFj?oc=5","date":"2025-07-31","type":"pipeline","source":"San Diego Business Journal","summary":"Transposon Shepherding Potential Treatment for ALS, Alzheimer’s - San Diego Business Journal","headline":"Transposon Shepherding Potential Treatment for ALS, Alzheimer’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxNeU5yQVh6WFJyejktS3ZKQTE5NG1JangyQU54UWtNRnQ5bGZFWllvaUJqZ3Fsam9LaW90bVlUYnY5VlpaWDZodS15U2E4anBhTWc2NXIzV0hpTzFVV0lOOEdUX01vNnpWdl9TN3lNTUtHQm44eGVtY01rN0kyZVI1ZlNXSkJ5bnVVWVoxb2tzYzRXSGdrMjNDQ2Fqdmtha3FYY2ZUdUZjR0paR09Jb2NUSDF4Y255YVRxdkE2Z1NVUjZXRkRRaFdRbG9kM0JjSDlQWUlkeTh6dDFlcjVHTzFPSi1OSkVKbFBja2drMmdaU3BfRVVoMm9EakhWQWpFcC0zTElWUE1VTi1kWlNzU1pqX3JqZkMwUFgzMUNIZGlmUlhkaG1jRFR6RnZIdTRZVmVkbklDRThMRXE?oc=5","date":"2025-05-28","type":"trial","source":"PR Newswire","summary":"Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS - PR Newswire","headline":"Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbnhqY1c5NDBrSlpXSFlXZWhtTHQtcndBN3gtX3MzbEZUN2RzaXpTd190QjdmYjhDQmdBbkUwcGZYZlpjdmZaTWtuRnBMX1J6ODVFWEZ6QnZMVy1PVG9ScUJCN3M2emh1Zlhxek1PQnJ1X3F5NlBXbDRFQVN6ZjBKS3BDOHJDR3BseEFqOUo0UXB6MzZyLTRsc3ZPS2pvZlF3aWYwWnZRRi04ejFMalNWaUp6U19mWnRj?oc=5","date":"2025-05-27","type":"pipeline","source":"Neurology Advisor","summary":"Diagnosis and Treatment Strategies for Early Alzheimer Disease: Highlights From AAN 2025 - Neurology Advisor","headline":"Diagnosis and Treatment Strategies for Early Alzheimer Disease: Highlights From AAN 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVy1lV0lGM3VfLVpNVC1SeFRURWwzOWREeWdBNHZOX3Q5Zklqd2Q5UHZDX01vNXowMW5LVGw5U0lkTGtvem9SQURFNFpOZGFvSGNRM2NHLUlPdGtpbWNUSzNuVC00NjBmQlk3NGhuSFVtMUJDVVRnVHdkR0JuN3YtQURiQUlGRTBFR2NSLVpZQm5PT1NyM2RqZ0QtcmVySnRkTG82RzJkd1M?oc=5","date":"2025-02-04","type":"pipeline","source":"Healio","summary":"IV edaravone may slow disease-progression milestones in ALS - Healio","headline":"IV edaravone may slow disease-progression milestones in ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOOFhyUl94cTNEaGt0Z1g4Q1lLWWVPU2VtRjBFZ05fUDVuN3lJYmhuTlBXcTdKeXZlMUJLcnRabFVqMGxXYUliRXFNN25ZOF9vY1FLaXluZEY5a1BHd2puTEtIUXpUbkVsNXNoTVdPS1dHT01MNlNyQnZaVDNsRTVZV01ZM3NLRW5rS2ZpRWwzMEY0N3c?oc=5","date":"2024-11-22","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: Novartis, Sage Therapeutics, Eli Lilly and more - Medical Marketing and Media","headline":"Rx Rundown: Novartis, Sage Therapeutics, Eli Lilly and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQNVd1ZXlQbzhfMThUMHFGRTgxQkpRR3ZiX0JZVlBpcWRSdjd2VEh3T3hNTjZpWmd1Vk02WEVfZVJQRkZ1QS1WOUJhNlhRNHY0b2h6Q1JpLVlYMnJCYnZjZ1RxSHZFSTgwLVJmYnhnQWV1Mm94TGlLbkVJblEyY0ItQlotOVJ5ZU1SZFFJSkpub0stU1lXVjhtTUNwZ3NXWGw4OE1QUFVNQ3FmYzVhNEVsNGE0NDJHc1k?oc=5","date":"2024-11-21","type":"deal","source":"Contract Pharma","summary":"Transposon Therapeutics Acquires Portfolio of Novel Nucleoside Analogs - Contract Pharma","headline":"Transposon Therapeutics Acquires Portfolio of Novel Nucleoside Analogs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQNnJhNV80bVd1cHh2RmVRdzhOcF9LcXc1Y3ZHLUhFaWFpLVVWbTBhaHdEOC1XMHowTEN6RjFFRWliUTJNVVRiQVFmTUd0UzJnMUNYRUZpWTJMRlp3dlpyNHBNTmJVbzEyYV9vdTAybVJwdVVKOG45OWhSblNtQTJ1SzQ5cW55ZXRnNUNuWGZGQ0U0UXc5Nks0aWd5ZUhIVFRFOGlFckxUQmQ0NmFDd0NxUENpZmE4N2NPUmtkaUM4ZHg1UzIzb3N3bzljVU1IX1pWSnoxWU9TRVc0bVRQX054Z3oxWk5xMktvXzJURlh5Z0dObl9kQUZSN2VlT1JRcE5tUzlULWh5YmpwYmtNeVRuSnEtV2FIV3V5dU9yd2hHc3R6eEhZQWEyZQ?oc=5","date":"2024-11-21","type":"pipeline","source":"PR Newswire","summary":"Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology - PR Newswire","headline":"Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNOU9GUmNZQUhtdmJHbm5hemlVX2k1YUpOUm9aTFExdGRwWVVRQzBYaWJpbXctRHNCS1V3c3o0MEc3VEVCc19wZ3kxWkREbHBYODFRXzlwMFN0SjFxNjBpWHZtQWR3QWdoMnNxalNNSzFISVRGYmxMTnhkek1ma291Y1l1VjFHdVdoMUkySmNjT0pBck80VEZOLWZ4RWdsQ01Cd2VxX0k2Z05kUy1acmRIUFBCWXRTZTZzZHhqS2pkNDVTNHJkd2ZLYnVrcnhnajRBZzJ5eXlxY0ZYdjRIb2REZ04yNUtnYnh5LVBQbWJVUVVfQWtFZ0wtNDVoOU42Z1hsbjhYdTBULXRjRHJ4NmFnR2ZKMlA4X3VMa0otajdlenp2djRFM3p5NjdTUE42S2JucEJrUkF3ajMzS2VDbkR3bg?oc=5","date":"2024-07-24","type":"trial","source":"PR Newswire","summary":"Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia - PR Newswire","headline":"Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Late","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQdnBSb2hPaTNsWjd2QkpzQkp4X2FYeFpRemVIVU0zNHZ6Y29wQ01jZkVZZXlVNlRtajMxOW9IS2h3VFNpSHNsQ3k5Zm9venRLWGVWcUZjVTlYSzNfWEstd3pVOGZRalZvNm1qYWRaa1I2NlVDNXdzYVVWSGlCYWE4YzVlTjlOZU5xT3JjUlFRcTJGNF90d2Z2dXNkeHlkOGUxQzRHb3RUMW1sTzNqYVpZb1Y1enNyM2xkdFlkcTBSU29lNEtvR3RKTFQxVUVsNGU4c2Rsd3dTTEdkQ0E1UEpUUThTYzB4YzA?oc=5","date":"2024-05-21","type":"regulatory","source":"PR Newswire","summary":"Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy - PR Newswire","headline":"Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}